Johnson & Johnson (NYSE:JNJ – Get Free Report) had its target price increased by analysts at JPMorgan Chase & Co. from $285.00 to $300.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 10.97% from the stock’s current price.
Other equities research analysts also recently issued reports about the company. Wells Fargo & Company increased their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. Bank of America reiterated a “neutral” rating and set a $278.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Finally, Johnson Rice cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $276.54.
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Trading Up 1.2%
Shares of JNJ stock traded up $3.21 during trading hours on Friday, reaching $270.35. 3,563,820 shares of the stock traded hands, compared to its average volume of 7,945,597. Johnson & Johnson has a 1-year low of $199.90 and a 1-year high of $290.25. The business has a fifty day moving average price of $267.43 and a 200 day moving average price of $250.79. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $650.82 billion, a PE ratio of 40.95, a PEG ratio of 2.74 and a beta of 0.22.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the business posted $2.80 EPS. The company’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.
Insiders Place Their Bets
In other news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.16% of the company’s stock.
Institutional Investors Weigh In On Johnson & Johnson
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $28,000. Navigoe LLC raised its holdings in Johnson & Johnson by 60.4% during the third quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after acquiring an additional 55 shares in the last quarter. Matrix Trust Co boosted its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares during the last quarter. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $43,000. Finally, Hanseatic Management Services Inc. acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $52,000. 69.55% of the stock is owned by institutional investors.
Latest Johnson & Johnson News
Here’s some of the latest news about JNJ:
- Positive Sentiment: J&J filed for FDA approval to expand CAPLYTA to bipolar I mania or mixed episodes, backed by two positive Phase 3 studies. Approval would add a potential indication and broaden the drug’s commercial opportunity. Article
- Positive Sentiment: Recent coverage highlighted promising prostate-cancer data for J&J’s $3.05 billion Halda acquisition, suggesting a possible longer-term pipeline catalyst. Article
- Negative Sentiment: ETFs were reported as net sellers of $144.2 million in J&J shares on Nov. 18, a potential near-term supply overhang; the report alone does not establish a lasting shift in investor sentiment. Article
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
